HRP20230052T1 - Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži - Google Patents
Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži Download PDFInfo
- Publication number
- HRP20230052T1 HRP20230052T1 HRP20230052TT HRP20230052T HRP20230052T1 HR P20230052 T1 HRP20230052 T1 HR P20230052T1 HR P20230052T T HRP20230052T T HR P20230052TT HR P20230052 T HRP20230052 T HR P20230052T HR P20230052 T1 HRP20230052 T1 HR P20230052T1
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- image
- aryl
- continued
- heteroaryl
- Prior art date
Links
- -1 1,3,4-oxadiazole sulfonamide derivative compounds Chemical class 0.000 title claims 4
- 229940122617 Histone deacetylase 6 inhibitor Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 32
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- HNUANCKZAPZYAA-UHFFFAOYSA-N 1,3,4-oxadiazole-2-sulfonamide Chemical class NS(=O)(=O)C1=NN=CO1 HNUANCKZAPZYAA-UHFFFAOYSA-N 0.000 claims 4
- 102000003964 Histone deacetylase Human genes 0.000 claims 4
- 108090000353 Histone deacetylase Proteins 0.000 claims 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 claims 2
- 208000031404 Chromosome Aberrations Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 206010010356 Congenital anomaly Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000012902 Nervous system disease Diseases 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 2
- 230000003542 behavioural effect Effects 0.000 claims 2
- 210000002808 connective tissue Anatomy 0.000 claims 2
- 208000010643 digestive system disease Diseases 0.000 claims 2
- 208000016097 disease of metabolism Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 208000030172 endocrine system disease Diseases 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 210000002346 musculoskeletal system Anatomy 0.000 claims 2
- 206010033675 panniculitis Diseases 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 208000023504 respiratory system disease Diseases 0.000 claims 2
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Claims (9)
1. Spoj derivata 1,3,4-oksadiazol sulfonamida, naznačen time, da je predstavljen sljedećom formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol:
[image]
u kojoj R1 je -CX2H ili -CX3;
R2 je -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), -(C1-C4alkil)-C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-O-C(=O)-(C1-C4 alkil), -(C1-C4 alkil)-NRARB, -(C1-C4 alkil)-aril, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril,
[image]
[image]
gdje najmanje jedan H iz skupina -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-O-C(=O)-O(C1-C4 alkil), ili -(C1-C4 alkil)-NRARB, može biti supstituiran s -X ili -OH,
najmanje jedan H iz skupina -(C1-C4 alkil)-aril, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril, može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -CF2H, -(C1-C4 alkil)-OH, -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-(C1-C4 alkil), -C(=O)-CF3, ili -C(=O)-CF2H, i
najmanje jedan H iz:
[image]
[image]
može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -NRARB, -CN, -(C1-C4 alkil), -CF3, -CF2H, -(C1-C4 alkil)-OH, -(C1-C4 alkil)-NRARB, -C(=O)-(C1-C4 alkil), -C(=O)-CF3, -C(=O)-CF2H, -C(=O)-NRARB, -C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-(C1-C4 alkil), -(C1-C4 alkil)-OC(=O)-CF2H, -(C3-C6 heterocikloalkil), -(C1-C4 alkil)-aril, -aril, ili -heteroaril, pri čemu najmanje jedan H iz -(C1-C4 alkil)-arila, -arila, ili -heteroarila, može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), ili -(C1-C4 alkil);
R3 je -H, -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 -aril, -heteroaril, alkil),
[image]
[image]
[image]
pri čemu najmanje jedan H iz skupina -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), ili -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), može biti supstituiran s -X ili -OH,
najmanje jedan H iz -arila ili -heteroarila, može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -CF2H, -(C1-C4 alkil)-OH, -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-(C1-C4 alkil), -C(=O)-CF3, -C(=O)-CF2H,
[image]
gdje najmanje jedan H iz
[image]
[image]
može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), ili -(C3-C6 heterocikloalkil);
R4 je -CX2H ili -CX3;
L1 je veza;
L2 je -(C1 alkilen)-;
svaki od L3 i L4 je neovisno veza ili -(C1-C2 alkilen)-;
svaki od Z1 do Z8 je neovisno N ili CRZ, gdje najmanje tri od Z1 do Z4 ili Z5 do Z8 ne mogu istovremeno biti N, i RZ je -H, -X ili -O(C1-C4 alkil);
svaki od Z9 do Z10 je neovisno N ili S;
svaki od Y1 do Y3 je neovisno -CH2-, -NRC-, -O-, ili -S(=O)2-;
svaki od Y4 do Y7 je neovisno -CH2-, -NRD-, ili -O-;
Y8 je -C(=O), -CH2-, ili -NRE-;
svaki od Y9 i Y10 je neovisno -NRF-, ili -S(=O)2-;
svaki od RA i RB je neovisno -H, -(C1-C4 alkil), -(C1-C4 alkil)-aril, -C(=O)-CF2H, ili -C(=O)-O(C1-C4 alkil);
svaki od RC do RE je neovisno -H, -(C1-C4 alkil), -(C1-C4 alkil)-OH, -(C1-C4 alkil)-O-(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -C(=O)-(C3-C7 cikloalkil), -(C1-C4 alkil)-C(=O)-(C2-C6 heterocikloalkil), -S(=O)2-(C1-C4 alkil), -(C1-C4 alkil)-aril, -(C2-C4 alkenil)-aril, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril,
[image]
ili
[image]
gdje najmanje jedan H iz skupina -(C1-C4 alkil)-aril, -(C2-C4 alkenil)-aril, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril,
[image]
može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), ili -CF3;
Y11 je -CH2-, -NRF-, ili -O-;
RF je -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-(C1-C4 alkil)-OH, -C(=O)-(C3-C7 cikloalkil), ili -S(=O)2-(C1-C4 alkil);
- - - - je jednostruka veza ili dvostruka veza, uz uvjet da kada je - - - - dvostruka veza, tada Y1 ili Y2 je -CH-;
svaki a do e je neovisno cijeli broj od 0, 1, 2 ili 3, uz uvjet da a i b ne mogu istovremeno biti 0, te c i d ne mogu istovremeno biti 0; i
X je F, Cl, Br ili I.
2. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da
R1 je -CX2H ili -CX3;
R2 je -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-O-C(=O)-(C1-C4 alkil), -(C1-C4 alkil)-NRARB, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril,
[image]
ili
[image]
gdje najmanje jedan H iz skupina -(C1-C4 alkil), -(C1-C4 alkil)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-O-C(=O)-(C1-C4 alkil), ili -(C1-C4 alkil)-NRARB, može biti supstituiran s -X ili -OH,
najmanje jedan H iz skupina -(C1-C4 alkil)-heteroaril, -aril, ili -heteroaril, može biti supstituiran sa skupinama -O(C1-C4 alkil), -(C1-C4 alkil), ili -(C1-C4 alkil)-OH, i
najmanje jedan H iz:
[image]
ili
[image]
može biti supstituiran sa skupinama -X, -OH, -NRARB, -CN, -(C1-C4 alkil), -(C1-C4 alkil)-OH, -(C1-C4 alkil)-NRARB, -C(=O)-NRARB, -C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-(C1-C4 alkil), -(C1-C4 alkil)-OC(=O)-CF2H, -(C3-C6 heterocikloalkil); -(C1-C4 alkil)-aril, -aril, ili -heteoaril, pri čemu najmanje jedan H iz -(C1-C4 alkil)-arila, -arila, ili -heteoarila, može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), ili -(C1-C4 alkil);
R3 je -H, -(C1-C4 alkil), -aril, -heteroaril,
[image]
[image]
[image]
ili
[image]
gdje najmanje jedan H iz -(C1-C4 alkila), može biti supstituiran s -X ili -OH;
najmanje jedan H iz -arila ili -heteroarila, može biti supstituiran sa skupinama -X, -O(C1-C4 alkil), -(C1-C4 alkil), -CF3, -C(=O)-(C1-C4 alkil),
[image]
ili
[image]
te najmanje jedan H iz
[image]
[image]
može biti supstituiran sa skupinama -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), ili -(C3-C6 heterocikloalkil);
R4 je -CX2H ili -CX3;
svaki od L1 do L4 je veza;
L2 je -(C1 alkilen)-;
L3 je veza ili -(C1-C2 alkilen)-;
svaki od Z1 do Z8 je neovisno N ili CRZ, gdje najmanje tri od Z1 do Z4 ili Z5 do Z8 ne mogu istovremeno biti N, i RZ je -H, -X ili -O(C1-C4 alkil);
svaki od Z9 do Z10 je neovisno N ili S;
svaki od Y1 do Y3 je neovisno -CH2-, -NRC-, -O-, ili -S(=O)2-;
svaki od Y4 do Y7 je neovisno -CH2-, -NRD-, ili -O-;
Y8 je -C(=O), -CH2-, ili -NRE-;
svaki od Y9 i Y10 je neovisno -NRF-, ili -S(=O)2-;
svaki od RA i RB je neovisno -H, -(C1-C4 alkil), -(C1-C4 alkil)-aril, -C(=O)-CF2H, ili -C(=O)-O(C1-C4 alkil);
svaki od RC do RE je neovisno -H, -(C1-C4 alkil), -(C1-C4 alkil)-OH, -(C1-C4 alkil)-O-(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-O(C1-C4 alkil), -C(=O)-(C3-C7 cikloalkil), -(C1-C4 alkil)-C(=O)-(C2-C6 heterocikloalkil), -S(=O)2-(C1-C4 alkil), -(C1-C4 alkil)-aril, -(C2-C4 alkenil)-aril, -(C1-C4 alkil)-heteroaril, -aril, -heteroaril,
[image]
ili
[image]
pri čemu najmanje jedan H iz -(C1-C4 alkil)-arila, -(C2-C4 alkenil)-arila, -(C1-C4 alkil)-heteroarila, -arila, -heteroarila,
[image]
može biti supstituiran sa skupinama -X, -OH, -O(C1-C4 alkil), -(C1-C4 alkil), ili CF3;
Y11 je -CH2-, -NRF-, ili -O-;
RF je -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-(C1-C4 alkil)-OH, -C(=O)-(C3-C7 cikloalkil), ili -S(=O)2-(C1-C4 alkil);
- - - - je jednostruka veza ili dvostruka veza, uz uvjet da kada je - - - - dvostruka veza, tada Y1 ili Y2 je -CH-;
svaki a do e je neovisno cijeli broj od 0, 1, 2 ili 3, uz uvjet da a i b ne mogu istovremeno biti 0, te c i d ne mogu istovremeno biti 0; i
X je F, Cl, Br ili I.
3. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 2, naznačen time, da
R1 je -CX2H;
R2 je -(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), -(C1-C4 alkil)-NRARB, -heteroaril,
[image]
pri čemu najmanje jedan H od skupina -(C1-C4 alkil), -(C1-C4 alkil)-C(=O)-O(C1-C4 alkil), ili -(C1-C4 alkil)-NRARB, može biti supstituiran s -X ili -OH,
najmanje jedan H od -heteroarila može biti supstituiran sa skupinama -O-(C1-C4 alkil), -(C1-C4 alkil), ili -(C1-C4 alkil)-OH, i najmanje jedan H od
[image]
može biti supstituiran sa skupinama -(C1-C4 alkil), ili -(C1-C4 alkil)-OH;
R3 je -aril, -heteroaril, ili
[image]
pri čemu najmanje jedan H od -arila ili -heteroarila može biti supstituiran sa skupinama -X, -O-(C1-C4 alkil), -(C1-C4 alkil), -CF3, ili -C(=O)-(C1-C4 alkil); i
najmanje jedan H od
[image]
može biti supstituiran sa -(C1-C4 alkilom);
svaki od L1 i L3 neovisno je veza;
L2 je -(C1 alkilen)-;
svaki od Z1 do Z8 je neovisno N ili CRZ, gdje najmanje dva od Z1 do Z4 ili Z5 do Z8 ne mogu istovremeno biti N, i RZ je -H, ili -X;
Y1 je -NRC-, -O-, ili -S(=O)2-;
Y2 je -CH2-, ili -NRC;
svaki od Y6 i Y7 je neovisno -O-;
Y8 je -CH2-;
svaki od RA i RB je neovisno -(C1-C4 alkil);
RC je -(C1-C4 alkil), -(C1-C4 alkil)-OH, -C(=O)-(C1-C4 alkil), -S(=O)2-(C1-C4 alkil), ili
[image]
gdje najmanje jedan H od
[image]
može biti supstituiran sa -(C1-C4 alkilom);
Y11 je -NRF-, ili -O-;
RF je -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-(C1-C4 alkil)-OH, ili -S(=O)2-(C1-C4 alkil);
- - - - je jednostruka veza;
svaki od a, b i e je neovisno cijeli broj od 0, 1 ili 2, uz uvjet da a i b ne mogu istovremeno biti 0; i
X je F, Cl, Br ili I.
4. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 3, naznačen time, da
R1 je -CX2H;
R2 je -(C1-C4 alkil), -(C1-C4 alkil)-NRARB,
[image]
ili
[image]
gdje najmanje jedan H od skupina -(C1-C4 alkil), -(C1-C4 alkil)-NRARB može biti supstituiran s -X, ili -OH, i
najmanje jedan H od
[image]
može biti supstituiran sa -(C1-C4 alkilom);
R3 je -aril, ili -heteroaril;
pri čemu najmanje jedan H od -arila, ili -heteroarila može biti supstituiran s -X ili -(C1-C4 alkilom);
svaki od L1 i L3 je neovisno veza;
L2 je -(C1 alkilen)-;
svaki od Z1 do Z4 je neovisno N ili CRZ, gdje najmanje dva od Z1 do Z4 ne mogu istovremeno biti N, i RZ je -H, ili -X;
Y1 je -NRC-, -O-, ili -S(=O)2-;
Y2 je -NRC;
svaki od RA i RB je neovisno -(C1-C4 alkil);
RC je -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -S(=O)2-(C1-C4 alkil), ili
[image]
gdje najmanje jedan H od
[image]
može biti supstituiran sa -(C1-C4 alkilom);
Y11 je -NRF-, ili -O-;
RF je -(C1-C4 alkil), -C(=O)-(C1-C4 alkil), -C(=O)-(C1-C4 alkil)-OH, ili -S(=O)2-(C1-C4 alkil);
- - - - je jednostruka veza;
svaki od a, b i e je neovisno cijeli broj od 0, 1 ili 2, uz uvjet da a i b ne mogu istovremeno biti 0; i
X je F, Cl ili Br.
5. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 1, naznačen time, da se spoj koji je predstavljen formulom I, bira iz skupine koja se sastoji od spojeva opisanih u sljedećoj tablici:
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
6. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 5, naznačen time, da se spoj koji je predstavljen formulom I, bira iz skupine koja se sastoji od spojeva opisanih u sljedećoj tablici:
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
7. Spoj derivata 1,3,4-oksadiazol sulfonamida, koji je predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema patentnom zahtjevu 6, naznačen time, da se spoj koji je predstavlje formulom I, bira iz skupine koja se sastoji od spojeva opisanih u sljedećoj tablici:
[image]
(nastavak)
[image]
(nastavak)
[image]
(nastavak)
[image]
8. Farmaceutski pripravak, naznačen time, da je za uporabu u prevenciji ili liječenju bolesti koja je posredovana histonskom deacetilazom, dok kao aktivni sastojak sadrži spoj koji je predstavljen formulom I, njegov stereoizomer ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od patentnih zahtjeva 1 do 7, pri čemu se bolest posredovana histonskom deacetilazom bira između infektivnih bolesti; neoplazmi; endokrinih, nutritivnih i metaboličkih bolesti; mentalnih poremećaja i poremećaja ponašanja; neuroloških bolesti; bolesti oka i adneksa; kardiovaskularnih bolesti; respiratornih bolesti; digestivnih bolesti; bolesti kože i potkožnog tkiva; bolesti mišićno-koštanog sustava i vezivnog tkiva; ili kongenitalnih malformacija, deformacija i kromosomskih abnormalnosti.
9. Spoj predstavljen formulom I, njegov stereoizomer ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time, da je za uporabu u postupku liječenja bolesti koja je posredovana histonskom deacetilazom, pri čemu postupak obuhvaća davanje terapijski učinkovite količine spoja predstavljenog formulom I, njegovog stereoizomera ili njegove farmaceutski prihvatljive soli,
pri čemu se bolest posredovana histonskom deacetilazom bira između infektivnih bolesti; neoplazmi; endokrinih, nutritivnih i metaboličkih bolesti; mentalnih poremećaja i poremećaja ponašanja; neuroloških bolesti; bolesti oka i adneksa; kardiovaskularnih bolesti; respiratornih bolesti; digestivnih bolesti; bolesti kože i potkožnog tkiva; bolesti mišićno-koštanog sustava i vezivnog tkiva; ili kongenitalnih malformacija, deformacija i kromosomskih abnormalnosti.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150105976 | 2015-07-27 | ||
PCT/KR2016/008214 WO2017018803A1 (en) | 2015-07-27 | 2016-07-27 | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
EP16830836.9A EP3328843B1 (en) | 2015-07-27 | 2016-07-27 | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20230052T1 true HRP20230052T1 (hr) | 2023-03-03 |
Family
ID=57886873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20230052TT HRP20230052T1 (hr) | 2015-07-27 | 2016-07-27 | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži |
Country Status (23)
Country | Link |
---|---|
US (1) | US10538498B2 (hr) |
EP (1) | EP3328843B1 (hr) |
JP (1) | JP6560436B2 (hr) |
KR (1) | KR101799007B1 (hr) |
CN (1) | CN107922362B (hr) |
AU (1) | AU2016299484B2 (hr) |
BR (1) | BR112018001720A2 (hr) |
CA (1) | CA2993929C (hr) |
DK (1) | DK3328843T3 (hr) |
ES (1) | ES2935932T3 (hr) |
FI (1) | FI3328843T3 (hr) |
HK (1) | HK1251571A1 (hr) |
HR (1) | HRP20230052T1 (hr) |
HU (1) | HUE061174T2 (hr) |
MX (1) | MX2018001193A (hr) |
MY (1) | MY197262A (hr) |
NZ (1) | NZ739026A (hr) |
PH (1) | PH12018500212A1 (hr) |
PL (1) | PL3328843T3 (hr) |
PT (1) | PT3328843T (hr) |
RU (1) | RU2697665C1 (hr) |
TW (1) | TWI639587B (hr) |
WO (1) | WO2017018803A1 (hr) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180002730A (ko) | 2015-05-07 | 2018-01-08 | 씨에이치디아이 파운데이션, 인코포레이티드 | 히스톤 탈아세틸효소 억제제 및 그것의 조성물 및 사용 방법 |
US10053434B2 (en) | 2015-05-07 | 2018-08-21 | Chdi Foundation, Inc. | Histone deacetylase inhibitors and compositions and methods of use thereof |
PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
EP3328844B1 (en) * | 2015-07-27 | 2019-11-27 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same |
MY197262A (en) | 2015-07-27 | 2023-06-08 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
MY197738A (en) * | 2015-08-04 | 2023-07-12 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
NZ740809A (en) * | 2015-10-12 | 2019-04-26 | Chong Kun Dang Pharmaceutical Corp | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
US11425910B2 (en) | 2017-02-21 | 2022-08-30 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
WO2018165520A1 (en) | 2017-03-10 | 2018-09-13 | Vps-3, Inc. | Metalloenzyme inhibitor compounds |
US20210101874A1 (en) * | 2017-04-03 | 2021-04-08 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
TW201910328A (zh) * | 2017-07-31 | 2019-03-16 | 日商武田藥品工業股份有限公司 | 雜環化合物 |
WO2019140265A1 (en) | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Trna synthetase inhibitors |
WO2019140254A1 (en) * | 2018-01-12 | 2019-07-18 | President And Fellows Of Harvard College | Multicyclic compounds and use of same for treating tuberculosis |
KR102316234B1 (ko) | 2018-07-26 | 2021-10-22 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
US20220008414A1 (en) * | 2018-11-23 | 2022-01-13 | Chong Kun Dang Pharmaceutical Corp. | Pharmaceutical composition comprising histone deacetylase 6 inhibitors |
JP7470058B2 (ja) | 2019-01-30 | 2024-04-17 | 武田薬品工業株式会社 | 複素環化合物 |
JP2022529695A (ja) | 2019-04-17 | 2022-06-23 | キマトリクス、エセ.エレ. | ヒストン脱アセチル化酵素阻害剤としての1,3,4-オキサジアゾール誘導体 |
MX2022003490A (es) | 2019-09-27 | 2022-04-25 | Takeda Pharmaceuticals Co | Derivados de 2-isoindol-1,3,4-oxadiazol utiles como inhibidores de la histona desacetilasa 6 (hdac6). |
CN114980887A (zh) | 2019-12-20 | 2022-08-30 | 特纳亚治疗股份有限公司 | 氟代烷基-噁二唑及其用途 |
KR102576148B1 (ko) * | 2020-04-13 | 2023-09-07 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이를 포함하는 약제학적 조성물 |
WO2022029041A1 (en) | 2020-08-07 | 2022-02-10 | Italfarmaco S.P.A. | 2-(4-((5-(benzo[b]thiophen-3-yl)-1h-tetrazol-1-yl)methyl)phenyl)-5-(difluoromethyl)-1,3,4-oxadiazole derivatives and similar compounds as selective inhibitors of histone deacetylase 6 (hdac6) for use in treating e.g. peripheral neuropathy |
KR20230146012A (ko) * | 2021-02-09 | 2023-10-18 | 셀진 코포레이션 | 연충 감염 및 질병의 치료를 위한 설폰아미드 및 이들의용도 |
KR20240013098A (ko) | 2021-04-23 | 2024-01-30 | 테나야 테라퓨틱스, 인코포레이티드 | 확장성 심근병증의 치료에 사용하기 위한 hdac6 억제제 |
TW202308619A (zh) * | 2021-05-04 | 2023-03-01 | 美商特納亞治療股份有限公司 | 用於治療代謝疾病和hfpef的hdac6抑制劑 |
CN114181187A (zh) * | 2021-11-24 | 2022-03-15 | 上海应用技术大学 | 一种4-甲磺酰胺基丁酰胺化合物的制备方法 |
TW202337446A (zh) * | 2022-01-28 | 2023-10-01 | 韓商鐘根堂股份有限公司 | 用於預防或治療肺動脈高血壓之組合物 |
KR20230144686A (ko) * | 2022-04-07 | 2023-10-17 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
KR20240035172A (ko) * | 2022-09-08 | 2024-03-15 | 주식회사 종근당 | 히스톤 탈아세틸화효소 6 억제제로서의 1,3,4-옥사다이아졸 유도체 화합물 및 이의 용도 |
Family Cites Families (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4871753A (en) | 1986-12-12 | 1989-10-03 | Ciba-Geigy Corporation | 3-Phenyl-5-trifluoromethyl-1,2,4-oxadiazole compounds which are useful pesticides |
KR100265385B1 (ko) | 1998-02-27 | 2000-11-01 | 윤여표 | 순환기 질환의 예방 및 치료 효능을 갖는 홍경천 추출물 |
US7868204B2 (en) | 2001-09-14 | 2011-01-11 | Methylgene Inc. | Inhibitors of histone deacetylase |
US6897220B2 (en) | 2001-09-14 | 2005-05-24 | Methylgene, Inc. | Inhibitors of histone deacetylase |
JP2005509606A (ja) | 2001-10-03 | 2005-04-14 | ファルマシア・コーポレーション | 凝血カスケードを選択的に阻害するのに有用な置換された多環式化合物のプロドラッグ |
IL162498A0 (en) * | 2001-12-20 | 2005-11-20 | Bristol Myers Squibb Co | (N-sulphonamido) acetamide derivatives and pharmaceutical compositions containing the same |
WO2007011626A2 (en) * | 2005-07-14 | 2007-01-25 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
CA2617557A1 (en) * | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Benzimidazole derivatives as sirtuin modulators |
WO2007032445A1 (ja) | 2005-09-16 | 2007-03-22 | Kyowa Hakko Kogyo Co., Ltd. | タンパク質キナーゼ阻害剤 |
GB0603041D0 (en) * | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
CN102008459B (zh) | 2006-03-23 | 2013-05-29 | 生物区科学管理控股有限公司 | 抗菌剂 |
TW200808707A (en) | 2006-06-14 | 2008-02-16 | Methylgene Inc | Sulfamide and sulfamate derivatives as histone deacetylase inhibitors |
EP1878730A1 (en) | 2006-07-12 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Substituted isoxazolines, pharmaceutical compositions containing the same, methods of preparing the same, and uses of the same |
MX2009006202A (es) | 2006-12-11 | 2009-06-22 | Genentech Inc | Composiciones y metodos para el tratamiento de neoplasma. |
WO2009010479A2 (en) | 2007-07-13 | 2009-01-22 | Euroscreen S.A. | Heterocyclic methylene piperidine derivatives and their use |
KR100903743B1 (ko) | 2007-08-28 | 2009-06-19 | 전병태 | 소화기계 질환개선 및 예방용 식품 조성물 |
EP2207811B1 (en) | 2007-11-02 | 2017-01-04 | Momenta Pharmaceuticals, Inc. | Non-anticoagulant polysaccharide compositions |
EP2217588A4 (en) | 2007-11-02 | 2013-12-04 | Methylgene Inc | INHIBITORS OF HISTONE DEACETYLASE |
CA2731730C (en) | 2008-07-23 | 2017-06-13 | President And Fellows Of Harvard College | Deacetylase inhibitors and uses thereof |
US20120136003A1 (en) * | 2009-04-20 | 2012-05-31 | Institute For Oneworld Health | Compounds, compositions and methods comprising 1,3,4-oxadiazole derivatives |
WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
JP2011008205A (ja) | 2009-05-27 | 2011-01-13 | Fujifilm Corp | 二軸性光学異方性膜を作製するための組成物 |
CA2768466C (en) | 2009-07-22 | 2018-08-14 | The Board Of Trustees Of The University Of Illinois | Hdac inhibitors and therapeutic methods using the same |
CN103221047B (zh) | 2010-01-13 | 2014-12-17 | 坦颇罗制药股份有限公司 | 化合物和方法 |
WO2011088192A1 (en) | 2010-01-13 | 2011-07-21 | Tempero Pharmaceuticals, Inc. | Compounds and methods |
NZ601655A (en) | 2010-01-22 | 2014-10-31 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
CN103108867A (zh) | 2010-02-25 | 2013-05-15 | 皮拉马尔企业有限公司 | 噁二唑化合物及其制备和用途 |
AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
RU2012153675A (ru) | 2010-05-12 | 2014-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные в качестве ингибиторов atr киназы |
US8697739B2 (en) * | 2010-07-29 | 2014-04-15 | Novartis Ag | Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof |
CA2820451C (en) | 2010-12-09 | 2017-12-12 | Wockhardt Limited | Ketolide compounds |
KR101262870B1 (ko) | 2011-01-28 | 2013-05-09 | 환인제약 주식회사 | 호장근 추출물을 함유하는 호흡기 질환의 예방 또는 치료용 조성물 |
ES2556822T3 (es) | 2011-07-08 | 2016-01-20 | Novartis Ag | Derivados de trifluorometil-oxadiazol novedosos y su uso en el tratamiento de enfermedad |
US9512083B2 (en) | 2011-07-20 | 2016-12-06 | The General Hospital Corporation | Histone deacetylase 6 selective inhibitors for the treatment of bone disease |
WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
EP2763531A4 (en) | 2011-10-03 | 2015-11-18 | Univ Columbia | NOVEL MOLECULES THAT INHIBIT HISTONE-DEACETYLASE 6 WITHIN HISTONE-DEACETYLASE 1 |
WO2013066835A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066838A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
WO2013066833A1 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods to inhibit histone deacetylase (hdac) enzymes |
WO2013066839A2 (en) | 2011-10-31 | 2013-05-10 | Glaxosmithkline Llc | Compounds and methods |
CA2856334A1 (en) | 2011-11-28 | 2013-06-06 | Christina Hebach | Novel trifluoromethyl-oxadiazole derivatives and their use in the treatment of disease |
JP6272773B2 (ja) | 2011-11-29 | 2018-01-31 | ナンジン アルゲン ファルマ カンパニー リミテッドNanjing Allgen Pharma Co. Ltd. | Hdac6阻害剤・抗腫瘍剤用複素環アミド化合物 |
AU2013230881A1 (en) | 2012-03-07 | 2014-10-30 | Board Of Trustees Of The University Of Illinois | Selective histone deactylase 6 inhibitors |
PL3041828T3 (pl) | 2013-09-06 | 2018-10-31 | Aurigene Discovery Technologies Limited | Pochodne 1,3,4-oksadiazolu i 1,3,4-tiadiazolu jako immunomodulatory |
JP2016540024A (ja) | 2013-12-12 | 2016-12-22 | チョン クン ダン ファーマシューティカル コーポレーション | 新規な選択的ヒストン脱アセチル化酵素阻害剤としてのアザインドール誘導体およびこれを含む薬剤学的組成物 |
CN104744446B (zh) | 2013-12-30 | 2019-06-25 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
EP3224252B1 (en) | 2014-11-24 | 2019-01-09 | Medifron Dbt Inc. | Substituted oxazole- and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands ii |
CN106349451B (zh) | 2015-07-14 | 2020-11-13 | 罗门哈斯公司 | 用于制备疏水改性环氧烷氨基甲酸酯聚合物的方法 |
PL3330259T3 (pl) | 2015-07-27 | 2021-02-08 | Chong Kun Dang Pharmaceutical Corp. | Związek pochodna amidowa 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 i kompozycja farmaceutyczna go zawierająca |
EP3328844B1 (en) | 2015-07-27 | 2019-11-27 | Chong Kun Dang Pharmaceutical Corp. | 1,3,4-oxadiazole sulfamide derivatives as histone deacetylase 6 inhibitor and pharmaceutical composition comprising the same |
MY197262A (en) | 2015-07-27 | 2023-06-08 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
MY197738A (en) | 2015-08-04 | 2023-07-12 | Chong Kun Dang Pharmaceutical Corp | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
NZ740809A (en) | 2015-10-12 | 2019-04-26 | Chong Kun Dang Pharmaceutical Corp | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same |
-
2016
- 2016-07-27 MY MYPI2018700258A patent/MY197262A/en unknown
- 2016-07-27 BR BR112018001720A patent/BR112018001720A2/pt active Search and Examination
- 2016-07-27 EP EP16830836.9A patent/EP3328843B1/en active Active
- 2016-07-27 NZ NZ739026A patent/NZ739026A/en unknown
- 2016-07-27 AU AU2016299484A patent/AU2016299484B2/en active Active
- 2016-07-27 PT PT168308369T patent/PT3328843T/pt unknown
- 2016-07-27 ES ES16830836T patent/ES2935932T3/es active Active
- 2016-07-27 CA CA2993929A patent/CA2993929C/en active Active
- 2016-07-27 MX MX2018001193A patent/MX2018001193A/es active IP Right Grant
- 2016-07-27 RU RU2018106877A patent/RU2697665C1/ru active
- 2016-07-27 FI FIEP16830836.9T patent/FI3328843T3/fi active
- 2016-07-27 PL PL16830836.9T patent/PL3328843T3/pl unknown
- 2016-07-27 WO PCT/KR2016/008214 patent/WO2017018803A1/en active Application Filing
- 2016-07-27 JP JP2018503804A patent/JP6560436B2/ja active Active
- 2016-07-27 CN CN201680044430.0A patent/CN107922362B/zh active Active
- 2016-07-27 KR KR1020160095332A patent/KR101799007B1/ko active IP Right Grant
- 2016-07-27 HR HRP20230052TT patent/HRP20230052T1/hr unknown
- 2016-07-27 US US15/747,952 patent/US10538498B2/en active Active
- 2016-07-27 HU HUE16830836A patent/HUE061174T2/hu unknown
- 2016-07-27 DK DK16830836.9T patent/DK3328843T3/da active
- 2016-07-27 TW TW105123824A patent/TWI639587B/zh active
-
2018
- 2018-01-26 PH PH12018500212A patent/PH12018500212A1/en unknown
- 2018-08-30 HK HK18111158.5A patent/HK1251571A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
MX2018001193A (es) | 2018-05-22 |
BR112018001720A2 (pt) | 2018-11-06 |
EP3328843B1 (en) | 2022-10-26 |
WO2017018803A1 (en) | 2017-02-02 |
HK1251571A1 (zh) | 2019-02-01 |
US10538498B2 (en) | 2020-01-21 |
ES2935932T3 (es) | 2023-03-13 |
JP6560436B2 (ja) | 2019-08-14 |
KR20170013836A (ko) | 2017-02-07 |
AU2016299484B2 (en) | 2019-08-01 |
KR101799007B1 (ko) | 2017-11-17 |
PT3328843T (pt) | 2023-01-24 |
CN107922362A (zh) | 2018-04-17 |
TWI639587B (zh) | 2018-11-01 |
CN107922362B (zh) | 2021-06-15 |
EP3328843A4 (en) | 2019-01-16 |
TW201712001A (zh) | 2017-04-01 |
FI3328843T3 (fi) | 2023-01-31 |
HUE061174T2 (hu) | 2023-05-28 |
US20180251437A1 (en) | 2018-09-06 |
RU2697665C1 (ru) | 2019-08-16 |
NZ739026A (en) | 2019-03-29 |
MY197262A (en) | 2023-06-08 |
PH12018500212A1 (en) | 2018-08-13 |
CA2993929C (en) | 2020-10-20 |
PL3328843T3 (pl) | 2023-02-27 |
AU2016299484A1 (en) | 2018-02-01 |
EP3328843A1 (en) | 2018-06-06 |
DK3328843T3 (da) | 2023-01-09 |
JP2018526343A (ja) | 2018-09-13 |
CA2993929A1 (en) | 2017-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20230052T1 (hr) | Spojevi derivata 1,3,4-oksadiazol sulfonamida kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
HRP20220003T1 (hr) | Spojevi derivata 1,3,4-oksadiazola kao inhibitori histonske deacetilaze 6, i farmaceutski pripravak koji ih sadrži | |
HRP20201304T1 (hr) | Spoj derivata 1,3,4-oksadiazol-amida koji služi kao inhibitor histonske deacetilaze 6 i farmaceutski pripravak koji sadrži taj spoj | |
HRP20161103T1 (hr) | Kemijski spojevi | |
HRP20181048T1 (hr) | Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja | |
RU2500681C2 (ru) | Замещенные гетероциклом пиперазинодигидротиенопиримидины | |
PH12018500773A1 (en) | Oxadiazole amine derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
PH12017501939B1 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
HRP20200561T1 (hr) | Prolijekovi spoja jak inhibitora za liječenje gastrointestinalnih upalnih bolesti | |
HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
HRP20180081T1 (hr) | Fuzionirani triciklični heterociklični spojevi kao inhibitori hiv integraze | |
HRP20211282T1 (hr) | Oksisteroli i postupci njihovog korištenja | |
HRP20161502T1 (hr) | Modulatori farmakokinetičkih svojstava lijekova | |
AR048334A1 (es) | Tetrahidrocarbazoles y sus derivados; metodos para su preparacion, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento y prevencion de enfermedades moduladas por agonistas de los receptores hepaticos lxralfa y/o lxrbeta. | |
RU2015107803A (ru) | Производные дигидроксипиримидинкарбоновой кислоты и их применение в лечении, облегчении или предотвращении вирусного заболевания | |
AR050615A1 (es) | Composiciones farmaceuticas para la administracion oral | |
WO2008042240A3 (en) | Enantiomerically pure phosphoindoles as hiv inhibitors | |
JP2011500621A5 (hr) | ||
JP2015514061A5 (hr) | ||
JP2018531289A5 (hr) | ||
MA34498B1 (fr) | Nouveaux co-cristaux d'agometaline leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
IN2014MN02562A (hr) | ||
HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
HRP20201473T1 (hr) | Inhibitori lizin gingipaina |